Effectiveness of Integrated Nurse-Led Interventions on Functional Trajectories, Sleep Quality, and Psychological Distress in Hemodialysis Patients: A Six-Month Randomized Controlled Trial

This randomized controlled clinical trial was conducted to evaluate the effectiveness of an integrated nurse-led multidimensional intervention on functional performance, sleep quality, and psychological distress among patients undergoing maintenance hemodialysis in Egypt. A total of 220 patients were randomly assigned to either an intervention group receiving structured nursing care or a control group receiving routine dialysis care. Outcomes were assessed at baseline, 12 weeks, and 6 months. The primary objective was to determine whether the intervention improved functional trajectories, while secondary objectives included evaluating its effects on sleep quality and psychological distress.

开始日期2025-08-05

申办/合作机构-

NCT01614795

/ Completed临床2期IIT

A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

This phase II trial studies how well cixutumumab and temsirolimus work in treating patients with recurrent or refractory sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cixutumumab and temsirolimus together may kill more tumor cells.

开始日期2012-06-18

申办/合作机构

National Cancer Institute

100 项与西妥木单抗相关的临床结果

登录后查看更多信息

100 项与西妥木单抗相关的转化医学

登录后查看更多信息

100 项与西妥木单抗相关的专利（医药）

登录后查看更多信息

188

项与西妥木单抗相关的文献（医药）

2026-07-01·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

New salidroside-furoxan hybrids as potential agents inhibit triple-negative breast cancer

Article

作者: Li, Na ; Zhang, Bing ; Zhang, Siqi ; Zhang, Yongqing ; Chen, Li

Salidroside (SAL) is a natural glycoside compound with various biological activities. Recent studies have shown that SAL exhibits certain therapeutic effects on triple-negative breast cancer (TNBC). To enhance the anti-TNBC activity, 15 SAL-furoxan hybrids were designed and synthesized. The anti-proliferative activities of all target compounds against four tumor cell lines (MDA-MB-231, MCF-7, BGC-823, and A549) and a normal human cell line (MCF-10A) were evaluated using the MTT assay. A12 demonstrated the most potent inhibitory activity on MDA-MB-231 cells (IC₅₀ = 14 nM), and lower toxicity compared to DOX (SI = IC_50(MCF-10A)/IC_{50(MDA-MB-231)}: 129.57 vs 1.01). Further research indicated that the anti-tumor mechanism of A12 involves the high amount of NO released in MDA-MB-231 cells and thereby induction of cells apoptosis.

2026-04-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design and evaluation of selective BET PROTACs with potent antitumor efficacy and safety against acute myeloid leukemia

Article

作者: Wei, Qingyun ; Zhou, Jinpei ; Zhang, Jian ; Zhang, Huibin ; Chen, Jiao ; Cao, Peng ; Wang, Bo ; Cai, Xueting

Targeting bromodomain and extra-terminal (BET) proteins is a promising therapeutic strategy for acute myeloid leukemia (AML). However, clinical development of conventional BET inhibitors has been limited by dose-related toxicities and compensatory resistance. Proteolysis-targeting chimeras (PROTACs) offer a catalytic and often more selective alternative by degrading target proteins via the ubiquitin-proteasome system. In this work, we designed and synthesized a series of novel BET PROTACs based on the clinical inhibitor ABBV-075. Through systematic optimization of linker length/composition and E3 ligase ligands (CRBN or VHL), we identified two highly potent PROTACs, A10 (CRBN-based) and A12 (VHL-based). Both compounds effectively degraded BET proteins, inhibited cell proliferation, induced cell-cycle arrest, and promoted apoptosis in MV4-11 AML cells. In MV4-11 xenograft models, A10 (6 mg/kg) and A12 (2 mg/kg) demonstrated significant tumor growth inhibition (76.2% and 60.5%, respectively). A comprehensive drug-likeness assessment revealed that while A12 exhibited higher systemic exposure in pharmacokinetic studies, A10 displayed a markedly superior safety profile with minimal hepatorenal toxicity. The favorable efficacy-safety balance of A10 underscores its strong potential as a preclinical candidate for AML therapy. This study highlights how rational PROTAC optimization can yield degraders with enhanced therapeutic windows, providing a promising path forward for targeted protein degradation in AML.

2026-03-26·JOURNAL OF MEDICINAL CHEMISTRY

Design and Synthesis of Pyrrolo[3,4- d ]pyrimidine-Based ATR Degraders for Effective Treatment of Colorectal Cancer in Mouse Model

Article

作者: He, Meng-Lan ; Garrido, Carmen ; Yu, Meng-Qian ; Lirussi, Frédéric ; Hui, Zi ; Feng, Xing-Lin ; Zhou, Jia-Wei ; Wang, Chen-Chen ; Ye, Lulu ; Mao, Nian-Dong ; Du, Bo-Qun ; Ye, Guo-Wei ; Zhang, Yu-Qing ; Ye, Xiang-Yang ; Wang, Zong-Hao ; Luo, Hui ; Yao, Xia ; Li, Shun-Ran ; Gao, Yuan

Ataxia telangiectasia and Rad3-related kinase (ATR) is a pivotal DNA damage response regulator. While several ATR inhibitors have entered clinical trials, none have yet been approved for therapeutic use. A potent ATR degrader A12 based on the pyrrolo[3,4-d]pyrimidine scaffold was designed and synthesized, with the ability not only to induce proteasomal degradation of ATR (DC₅₀: 127 nM, D_max: 72%) but also of CHK1 (DC₅₀: 135 nM, D_max: 70%) in several colorectal cancer cells. It exhibits strong antiproliferative activity (IC₅₀: 55 nM) and rapidly triggers apoptosis. In LoVo xenograft mouse model, A12 monotherapy (30 mg/kg) achieved outstanding tumor growth inhibition (TGI: 74%) without apparent toxicity. Combination with A12 (10 mg/kg) and cetuximab (3 mg/kg) further enhanced efficacy (TGI: 81%) with a favorable safety profile. These findings highlight that ATR degraders such as A12, which also degrade CHK1 simultaneously, represents as a promising therapeutic strategy for colorectal cancer and potentially other tumor types.

109

项与西妥木单抗相关的新闻（医药）

2026-05-13

·北京医学感染与传染研究

国际抗微生物制剂杂志 67卷 1-5期

International Journal of Antimicrobial Agents Volume 67, Issue 1 国际抗微生物制剂杂志 67卷 1期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/1 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会新闻与信息页） 1 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与信息页 Article 107688 Antimicrobial Pharmacometrics（抗菌药物药代动力学） 2 Model-informed precision pyrazinamide dosing: The establishment of a population pharmacokinetic model repository for clinical decision support 基于模型的精准吡嗪酰胺剂量调整：建立用于临床决策支持的人群药代动力学模型库 Huan Zhang, Lu Han, Xiao-Qin Liu, Juan Wang, ... Zheng Jiao Article 107658 Global Landscape of Phage Therapy（噬菌体治疗的全球概况） 3 Nanomedicine for phage therapy: Encapsulation strategies for enhanced antimicrobial efficacy 噬菌体治疗的纳米医学：增强抗菌功效的封装策略 Alexis Dorta-Gorrín, Verónica Salgueiriño, Lorena García-Hevia Article 107660 4 Antibiotic-mediated prophage activation: Mechanisms, consequences, and therapeutic implications 抗生素介导的原噬菌体激活：机制、后果及治疗意义 Damir Gavric, Petar Knezevic Article 107655 5 Phage therapy for KPC-producing Klebsiella pneumoniae decolonization in high-risk patients: The KIDNAP Study Protocol – A prospective feasibility and proof of concept study in the Brazilian context 噬菌体治疗高风险患者中产KPC肺炎克雷伯菌的定植清除：KIDNAP研究方案——巴西背景下的一项前瞻性可行性及概念验证研究 Iris Najjar, Larissa Simão Gandolpho, Jôiciglecia Pereira dos Santos, Camila de Paula Siqueira, ... Ana C. Gales Article 107673 AI strategies to combat AMR（人工智能对抗抗菌药物耐药性的策略） 6 Development and validation of machine learning models to predict vancomycin- and teicoplanin-associated acute kidney injury: A retrospective, multicenter study 开发和验证机器学习模型用以预测万古霉素和替考拉宁相关的急性肾损伤：一项回顾性、多中心研究 Pin-Yi Lo, Fan-Ying Chan, Yi-En Ku, San-Yuan Wang, Hsiang-Yin Chen Article 107651 Reviews（综述） 7 A systematic review and meta-analysis of the global epidemiology of carbapenem-resistant Escherichia coli 碳青霉烯耐药大肠埃希菌全球流行病学的系统综述和荟萃分析 Mikaela M. Walker, Jason A. Roberts, Yixuan Li, Fekade B. Sime Article 107668 8 Molecular mechanisms of resistance and tolerance of Staphylococcus aureus to daptomycin 金黄色葡萄球菌对达托霉素耐药和耐受的分子机制 Candice Lim, Geoffrey W. Coombs, Shakeel Mowlaboccus Article 107678 Full Length Articles（长篇论著） 9 Antimicrobial peptide CATH-1 combats Streptococcus suis by targeting serine/threonine kinase 抗菌肽CATH-1通过靶向丝氨酸/苏氨酸激酶对抗猪链球菌 Yi Lu, Xiaoying Yu, Yandi Pan, Hang Yin, ... Rendong Fang Article 107656 10 The antiarrhythmic drugs dronedarone and amiodarone exhibit potent in vitro and in vivo activity against Clostridioides difficile 抗心律失常药物决奈达隆和胺碘酮对艰难梭菌表现出强效的体内外活性 Ahmed A. Abouelkhair, Nader S. Abutaleb, Mohamed N. Seleem Article 107649 11 Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Türkiye: A multi-centre retrospective matched-cohort study 头孢他啶-阿维巴坦与土耳其其他适当抗菌疗法治疗产OXA-48或KPC的肠杆菌目感染的比较：一项多中心回顾性匹配队列研究 Abdullah Tarık Aslan, Elif Seren Tanriverdi, Sibel Yıldız Kaya, Gozde Dalgan, ... Murat Akova Article 107650 12 An easy-to-use predictive score for identifying patients at risk of suboptimal linezolid exposure and candidates for therapeutic drug monitoring 一种易于使用的预测评分，用于识别存在利奈唑胺暴露不足风险及需进行治疗药物监测的患者 Daniel Fresán, Luisa Sorlí, Jaume Barceló-Vidal, Ana Rodrigo-Moreno, ... Sonia Luque Article 107661 13 Urinary exosome-derived microRNAs as biomarkers of tenofovir disoproxil fumarate (TDF)-induced renal toxicity in people with HIV-1 尿液外泌体衍生的微小RNA作为HIV-1感染者使用富马酸替诺福韦二吡呋酯（TDF）引起肾毒性的生物标志物 José L. Casado, Pilar Vizcarra, Francisco J. Hernández-Walias, José Manuel del Rey, ... Alejandro Vallejo Article 107654 14 Global genomic epidemiology of carbapenemase-producing Klebsiella pneumoniae, 1996–2023 1996-2023年产碳青霉烯酶肺炎克雷伯菌的全球基因组流行病学 Yuxia Shi, Dongxiao Ru, Minge Wang, Shengliang Cao, ... Jianbiao Lu Article 107657 15 Two Tail Protein-Derived Capsule Depolymerases From Phage vB_KpnS_GH-K1 are Effective Against Pneumonia Caused by K2 Serotype Klebsiella pneumoniae 来自噬菌体vB_KpnS_GH-K1的两种尾蛋白衍生的荚膜多糖解聚酶对K2血清型肺炎克雷伯菌引起的肺炎有效 Guiyang Ge, Hongbei Ge, Jianhui Xu, Bing Yue, ... Rui Du Article 107662 16 Discrepancy between WGS-based genotypic and phenotypic drug susceptibility testing of first and second-line drugs for Mycobacterium tuberculosis: Limited impact of unknown resistance mechanisms 结核分枝杆菌一线和二线药物基于全基因组测序的基因型与表型药物敏感性测试之间的差异：未知耐药机制的影响有限 Ruimin Hong, Peng Xu, Wenjie Lai, Chi Wu, ... Qian Gao Article 107666 17 Consumption and expenditure on fidaxomicin and oral vancomycin for Clostridioides difficile infection: A 12-year longitudinal study of 43 countries and regions 43个国家和地区12年艰难梭菌感染使用菲达霉素和口服万古霉素的消费和支出情况纵向研究 Yin Zhang, Xue Li, Angel Y.S. Wong, Vincent K.C. Yan, ... Wai K. Leung Article 107664 18 Genome-wide insight into the evolution and global transmission of tigecycline resistant tet(X4)-carrying Klebsiella species across reservoirs 全基因组视角下携带耐替加环素tet(X4)的克雷伯菌属在各储存库中的进化与全球传播 Yuye Wu, Yawen Yu, Xueqian He, Weifang Mao, ... Zhi Ruan Article 107665 19 Combined disk-based tests for phenotypic identification of KPC variants in Enterobacterales 基于联合药敏试验的肠杆菌目中KPC变异体的表型鉴定 Feng Yang, Li Ding, Siquan Shen, Chengkang Tang, ... Fupin Hu Article 107663 20 Impact of antimicrobial resistance measures and the emergence of COVID-19 on antimicrobial use throughout the Japanese population: A retrospective cohort study using a national claims database 抗菌药物耐药性措施的实施及新冠疫情的出现对日本全民抗菌药物使用的影响：一项使用国家索赔数据库的回顾性队列研究 Ryuji Koizumi, Shinya Tsuzuki, Yusuke Asai, Kensuke Aoyagi, Norio Ohmagari Article 107667 21 Ceftazidime-avibactam resistance among clinical isolates of Citrobacter freundii, Morganella morganii, Providencia spp. and Serratia marcescens across five continents: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016–2023 2016-2023年抗菌药物测试领导与监测（ATLAS）项目数据：五大洲弗氏柠檬酸杆菌、摩氏摩根菌、普罗维登斯菌属和产气肠杆菌临床分离株对头孢他啶-阿维巴坦的耐药性 Hao-En Jan, Jiun-Ling Wang, Nan-Yao Lee, Shun-Chung Hsueh, ... Po-Ren Hsueh Article 107669 22 Impact of DNA-stored mutations on virological response in virologically suppressed PWH in the switch to modern regimens DNA储存突变对病毒抑制的HIV感染者转换至现今治疗方案时病毒学反应的影响 Francesca Lombardi, Elio Gentilini Cacciola, Federica Carli, Francesco Saladini, ... Maria Mercedes Santoro Article 107670 23 NucS Thr74Ile confers mutator phenotype in a globally disseminated clinical Mycobacterium abscessus subsp. abscessus clone NucS Thr74Ile在全球传播的临床脓肿分枝杆菌脓肿亚种克隆中赋予突变表型 Juan Li, Junsheng Fan, Zhili Tan, Anqi Li, ... Haiqing Chu Article 107677 24 Adverse effects of posaconazole on adrenal steroid biosynthesis: An integrative approach using FAERS-based pharmacovigilance and systematic review with meta-analysis of randomised controlled trials 泊沙康唑对肾上腺类固醇生物合成的不良影响：基于FAERS的药物警戒和随机对照试验系统综述与荟萃分析的综合方法 Yuki Nakano, Kazumasa Kotake, Yuki Asai, Masayuki Murata, ... Hirotsugu Hasuwa Article 107676 25 SU3327: A multi-target compound targeting bacterial menaquinone and DNA SU3327：一种靶向细菌甲基萘醌和DNA的多靶点化合物 Shuge Wang, Ke Zhao, Ziqi Chen, Chengtao Sun, ... Dejun Liu Article 107679 26 blaKPC-2 amplification and a novel mrcA mutation drive Cefiderocol heteroresistance in ST11 CRKP blaKPC-2扩增和一种新型mrcA突变驱动ST11碳青霉烯耐药肺炎克雷伯菌对头孢地尔的异质性耐药 Yuxuan Liu, Hanxu Hong, QianBin Dai, Linping Fan, ... Yang Liu Article 107682 27 P1-like phage-plasmids drive blaCTX-M-27 transmission through lysogenic conversion and transposition P1样噬菌体质粒通过溶原性转换和转座驱动blaCTX-M-27传播 Zengfeng Zhang, Chunlei Shi Article 107686 28 Streptomyces taklimakanensis sp. nov. TRM43335 produces 3-indole carbaldehyde a promising inhibitor of carbapenem-resistant Acinetobacter baumannii: In vitro and in vivo evaluation 塔克拉玛干沙漠放线菌新种Streptomyces taklimakanensis sp. nov. TRM43335产生3-吲哚甲醛——一种有前景的碳青霉烯耐药鲍曼不动杆菌抑制剂：体内外评估 Yanchun Qin, Wen ting Zhou, Ling Wang, Shengqiang Yang, ... Hong Zeng Article 107685 Short Communications（短篇通讯） 29 Fluconazole exposure during mechanical circulatory support (MCS) device insertion 机械循环支持（MCS）装置植入期间的氟康唑暴露 Kelly A. Cairns, Kate Morton, Trisha N. Peel, Iain J. Abbott, ... Michael J. Dooley Article 107647 30 Evaluation of sulbactam-durlobactam disk diffusion and broth microdilution methods for Acinetobacter baumannii 评估磺苄西林-杜洛巴坦对鲍曼不动杆菌的纸片扩散法和肉汤微量稀释法 Xiaolan Hong, Xinying Wang, Xin Xiang, Siquan Shen, ... Yan Guo Article 107659 Letters to the Editor（读者来信） 31 Comment on “Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Turkiye: A multi-centre retrospective matched-cohort study” 对“土耳其头孢他啶-阿维巴坦与其他适当抗菌疗法治疗产OXA-48或KPC的肠杆菌目感染的比较：一项多中心回顾性匹配队列研究”的评论 S. Dhanya Dedeepya, Vaishali Goel, Nivedita Nikhil Desai Article 107671 32 Emergence of TMexCD-TOprJ-producing Vibrio furnissii in retail shellfish 零售贝类中出现产TMexCD-TOprJ的弗尼斯弧菌 Haotian Deng, Zhongpeng Cai, Kexin Li, Ludan Xiao, ... Shaowen Li Article 107680 International Journal of Antimicrobial Agents Volume 67, Issue 2 国际抗微生物制剂杂志 67卷 2期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/2 1 Title Page & Editorial Board 标题页与编委会 Article 107727 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与信息页） 2 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与信息页 Article 107719 Systematic Reviews and Meta-analyses（系统综述与荟萃分析） 3 Ceftazidime/avibactam and ceftolozane/tazobactam for severe paediatric infections: A systematic review, meta-analysis, and evidence map 头孢他啶/阿维巴坦与头孢洛扎/他唑巴坦治疗儿童重症感染：一项系统评价、荟萃分析及证据图谱研究 Paula Pimenta-de-Souza, Alice Ramos-Silva, Valcieny Sandes, Patrícia Portella, ... Elisangela Costa Lima Article 107710 Full Length Articles（长篇论著） 4 Downregulation of an NfsA-like nitroreductase causes metronidazole resistance in Gardnerella vaginalis NfsA样硝基还原酶下调可导致阴道加德纳菌对甲硝唑耐药 Ana Paunkov, Anna-Lena Mayr, Vera Oberbauer, Timo Schwebs, ... David Leitsch Article 107681 5 Machine–learning and gene–synergy networks reveal interpretable drivers of antibiotic resistance in Staphylococcus aureus 机器学习与基因协同网络揭示金黄色葡萄球菌抗生素耐药性的可解释驱动因素 Jie Xu, Yuan Li, Ying Wang, Fang Liu, ... Haiyan Yang Article 107690 6 Enhanced molecular surveillance for gonococcal resistance during doxycycline post-exposure prophylaxis implementation 在实施多西环素暴露后预防措施期间加强对淋球菌耐药的分子监测 Ziyuan Zhao, Leshan Xiu, Junping Peng Article 107689 7 Fosfomycin-based combinations against carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Correlating in vitro synergy with clinical outcomes 以磷霉素为基础的联合用药治疗产碳青霉烯酶肺炎克雷伯菌血流感染：体外协同作用与临床预后的相关性 Melike Törüyenler Coşkunpınar, Güle Çınar, Duygu Öcal, İsmail Balık Article 107687 8 EnvZ mutation–driven downregulation of catecholate siderophore receptors and concurrent TonB complex repression confer cefiderocol resistance in a KPC-producing ST11-KL64 hypervirulent Klebsiella pneumoniae EnvZ突变驱动儿茶酚酸铁载体受体下调表达，同时抑制TonB复合体，使产KPC酶的ST11-KL64型高毒力肺炎克雷伯菌对头孢地尔产生耐药性 Danni Pu, Xianxia Zhuo, Rongrong Song, Chunhui Wang, ... Bin Cao Article 107693 9 Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis 治疗肾盂肾炎和复杂性尿路感染的抗生素类别比较：一项系统综述和荟萃分析 Digbijay Kunwar, Itay Zahavi, Judit Olchowski, Hagar Dallasheh, Mical Paul Article 107696 10 Enhancing meropenem therapy in critical care: A retrospective study of PK/PD target attainment and therapeutic drug monitoring 强化重症监护病房中美罗培南的治疗：一项关于药代动力学/药效学目标达成情况及治疗药物监测的回顾性研究 Jingli Liao, Chao Li, Jingxian Liu, Wei Wu, ... Lixia Li Article 107697 11 Zinc deficiency reverses biofilm azole resistance in Candida albicans 锌缺乏可逆转白色念珠菌生物膜对唑类药物的耐药性 Yingzhe Wang, Shigan Ye, Yuan Deng, Yingting Huang, Xiaoliang Zhu Article 107695 12 Development of ceftazidime–avibactam resistance driven by conversion of blaKPC-2 to blaKPC-78 during treatment of ST463 carbapenem-resistant Pseudomonas aeruginosa infection 治疗ST463型碳青霉烯类耐药铜绿假单胞菌感染过程中，因blaKPC-2基因突变为blaKPC-78基因而引发的头孢他啶-阿维巴坦耐药性的产生 Haotian Xu, Tingjuan Zhang, Xueying Cui, Jingyi Guo, ... Xi Li Article 107703 13 ATP-binding cassette transporters mediate and regulate metronidazole resistance in Clostridioides difficile ATP结合盒转运蛋白介导并调控艰难梭菌对甲硝唑的耐药性 Teng Xu, Ying Zhou, Qingqing Xu, Li Wang, ... Haihui Huang Article 107709 14 Regorafenib, a multitargeted kinase inhibitor, inhibits enterovirus 71 infection by suppressing the MAPK pathway 瑞戈非尼（Regorafenib）作为一种多靶点激酶抑制剂，可通过抑制丝裂原活化蛋白激酶（MAPK）通路来抑制肠道病毒71型感染 Xinyu Zhang, Yuanyuan Cao, Yu Liu, Shengqun Deng, ... Qi Tang Article 107711 Short Communications（短篇通讯） 15 Effect of ibuprofen on the pharmacokinetics of intravenous flucloxacillin in healthy adults 布洛芬对健康成年人静脉注射氟氯西林药代动力学的影响 Alison Boast, Amy Legg, James McCarthy, Jason A Roberts, ... Amanda Gwee Article 107684 16 Formation of a novel multiresistance plasmid co-carrying tigecycline, carbapenem, and other resistance genes by recombination during conjugative transfer in Klebsiella pneumoniae 肺炎克雷伯菌在接合转移过程中通过重组形成一种共携带替加环素、碳青霉烯类及其他耐药基因的新型多重耐药质粒 Runhao Yu, Zhong Chen, Stefan Schwarz, Hong Yao, ... Xiang-Dang Du Article 107683 17 Vancomycin clearance compared to creatinine clearance by timed urine collection in the intensive care unit 重症监护室中通过定时尿液收集法比较万古霉素清除率与肌酐清除率 Andrew Chantha Hean, Rinoj Mathew, Frank Chu, Linda Awdishu Article 107704 18 Risk of infective endocarditis in oncohaematological patients undergoing active treatment with Enterococcus faecalis bloodstream infection: A retrospective multicentre study 接受积极治疗的血液肿瘤患者合并屎肠球菌（Enterococcus faecalis）血流感染时发生感染性心内膜炎的风险：一项回顾性多中心研究 Miguel Ángel Consuegra Pérez, Sara Grillo, Alexander Rombauts, María Alba Rivera Martínez, ... Laura Escolà-Vergé Article 107706 Letters to the Editor（致编辑的信） 19 In reply to the letter to editor regarding “Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Turkiye: A multi-centre retrospective matched-cohort study” 针对就《土耳其头孢他啶-阿维巴坦与其他适宜抗菌疗法治疗产OXA-48或KPC肠杆菌科感染的对比：一项多中心回顾性匹配队列研究》一文致编辑的信的回复 Abdullah T. Aslan, Patrick N.A. Harris, David L. Paterson Article 107691 20 Aztreonam–avibactam pharmacokinetics during extracorporeal membrane oxygenation support: First insights from a case report 体外膜肺氧合支持期间氨曲南-阿维巴坦的药代动力学特征：首例病例报告的初步见解 Alba Pau-Parra, Sònia Luque, Laura Doménech, María Martínez-Pla, ... Jordi Riera Article 107692 21 Comments on ‘Acute kidney injury associated with colistin sulphate vs. polymyxin B sulphate therapy: A real-world, retrospective cohort study’ 对“硫酸黏菌素与硫酸多黏菌素B治疗相关急性肾损伤：一项真实世界回顾性队列研究”的评论 Genzhu Wang Article 107702 22 Superintegron of Vibrio paracholerae as a reservoir of antibiotic resistance genes 副霍乱弧菌（或拟霍乱弧菌）超级整合子作为抗生素耐药基因的储存库 Sergio Mascarenhas Morgado, Erica Lourenço da Fonseca, Ana Carolina Paulo Vicente Article 107708 23 Clinical outcomes of metronidazole dosing strategies in obese patients with Bacteroides bloodstream infections 肥胖患者脆弱拟杆菌（Bacteroides）血流感染时甲硝唑不同给药策略的临床疗效 Sunish Shah, Rachel V. Marini, Dayna McManus, Ryan K. Shields, ... Tyler Tate Article 107701 Corrigendum（勘误表） 24 Corrigendum to “Impact of antimicrobial resistance measures and the emergence of COVID-19 on antimicrobial use throughout the Japanese population: A retrospective cohort study using a national claims database” [International Journal of Antimicrobial Agents Volume 67(2026)107667] 对《抗菌药物耐药性评估及新冠疫情的爆发对日本全民抗菌药物使用情况的影响：一项基于国家医保理赔数据库的回顾性队列研究》[《国际抗微生物制剂杂志》第67卷（2026年）第107667篇]的勘误说明 Ryuji Koizumi, Shinya Tsuzuki, Yusuke Asai, Kensuke Aoyagi, Norio Ohmagari Article 107694 International Journal of Antimicrobial Agents Volume 67, Issue 3 国际抗微生物制剂杂志 67卷3期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/3 1 Title Page & Editorial Board 目录与编委会 Article 107753 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与资讯页面） 2 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与资讯页面 Article 107746 Hot Topic（热点） 3 Artificial intelligence and machine learning in antimicrobial discovery, resistance prediction, and precision therapy 人工智能与机器学习在抗菌药物发现、耐药性预测及精准治疗中的应用 Reema Singh, Yu-Wei Lin, Jinxin Zhao, Jian Li Article 107715 Reviews（综述） 4 Pharmacokinetics and pharmacodynamics of bacteriophage therapy: A scoping review 噬菌体治疗的药代动力学和药效学：一项范围综述 Andrew T Nguyen, Nicita Mehta, KaiLan Mackey, Thomas Cummiskey, ... Jason Young Article 107705 5 Effect of probiotic strain, duration, and dose on preventing ICU-acquired infection: A scoping review 益生菌菌株、疗程及剂量对预防重症监护病房（ICU）获得性感染的影响：一项范围综述 Aqdar Mufareh Al-Aklabi, Sara Muteb Alotaishan, Yasmin Youssuf Al-Gindan, Rabie Yousif Khattab Article 107714 Full Length Articles（完整论著） 6 Pharmacokinetics of ampicillin, sulbactam and combined ampicillin/sulbactam in subcutis, muscle and plasma: A microdialysis trial in healthy volunteers 氨苄西林、舒巴坦及氨苄西林/舒巴坦联合用药在皮下、肌肉和血浆中的药代动力学：一项健康志愿者微透析试验 Anselm Jorda, Lena Pracher, Marlene Prager, Felix Bergmann, ... Valentin al Jalali Article 107716 7 Beneficial effects of a compound probiotic in Helicobacter pylori-infected patients aged over 40 years: An open-label randomised clinical trial 复合益生菌对40岁以上幽门螺杆菌感染患者的有益作用：一项开放标签随机临床试验 Chenghai Yang, Jie Cheng, Meng Zhang, Bingyun Lu, ... Ye Chen Article 107712 8 Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis 内脏利什曼病（黑热病）后皮肤利什曼原虫病患者的皮肤药代动力学与药效学 Wan-Yu Chu, Om Prakash Singh, Shyam Sundar, Krishna Pandey, ... Thomas P. C Dorlo Article 107713 9 Amodiaquine hydrochloride facilitates mycobacterial clearance via triggering autophagy in macrophages 盐酸阿莫地喹通过触发巨噬细胞自噬促进分枝杆菌清除 Hongxuan Yan, Jinfeng Yuan, Shujuan Duan, Fuzhen Zhang, ... Mengqiu Gao Article 107720 Short Communications（短篇通讯） 10 Risk factors for bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii in ICU patients with any site colonisation: a prospective observational study 重症监护病房（ICU）患者任何部位定植碳青霉烯耐药鲍曼不动杆菌造成血流感染的危险因素：一项前瞻性观察研究 Giusy Tiseo, Valentina Galfo, Aurelio Lepore, Manuela Pogliaghi, ... Marco Falcone Article 107717 11 Resistance to sulbactam/durlobactam in carbapenem-resistant Acinetobacter baumannii in treatment-naive setting: in vitro data and genomic insights from Italian bloodstream isolates 初次用药背景下耐碳青霉烯鲍曼不动杆菌对舒巴坦/杜洛巴坦的耐药性：来自意大利血流感染分离株的体外数据及基因组见解 Gabriele Bianco, Gherard Batisti Biffignandi, Matteo Boattini, Sara Comini, ... Paolo Gaibani Article 107718 12 Real-world daptomycin use with a focus on muscle toxicity: A multicentric retrospective study 聚焦肌肉毒性的达托霉素实际使用情况：一项多中心回顾性研究 C. Airaud, E. Demay, V. Dias Meireles, D. Luque Paz, ... A. Bacle Article 107721 International Journal of Antimicrobial Agents Volume 67, Issue 4 国际抗微生物制剂杂志 67卷4期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/4 1 Title Page & Editorial Board 目录与编者按 Article 107775 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与信息） 2 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与信息 Article 107765 Hot Topic（热点） 3 Phage therapy in China: Arming the One Health approach 中国噬菌体疗法：助力“同一健康”策略实施 Na Li, Qimao Yang, Bijie Hu, Tongyu Zhu, Nannan Wu Article 107731 Global Landscape of Phage Therapy（噬菌体疗法的全球概况） 4 CRISPR/Cas9-engineered Salmonella phage displaying antimicrobial peptide LL37 for enhanced antibacterial activity 利用CRISPR/Cas9技术改造的沙门氏菌噬菌体，展示出抗菌肽LL37，用以增强抗菌活性 Su Jin Jo, Se Chang Park, Sang Guen Kim Article 107734 5 Phage resistance bidirectionally altered antibiotic susceptibility in Klebsiella pneumoniae via galE mutation 噬菌体抗性通过galE基因突变双向改变肺炎克雷伯菌的抗生素敏感性 Braira Wahid, Sue C. Nang, Jinxin Zhao, Zhi Ying Kho, ... Jian Li Article 107738 Reviews（综述） 6 Resistance of uropathogens to gepotidacin: A systematic review of in vitro antimicrobial susceptibility studies 尿路病原体对吉培西林（gepotidacin，一种新型抗菌药）的耐药性：体外抗菌敏感性研究的系统综述 Matthew E. Falagas, Laura T. Romanos, Eleni D. Katritsi, Iva D. Tzvetanova Article 107723 Full Length Articles（完整论著） 7 Identification of KPC-271, a novel KPC variant conferring ceftazidime-avibactam resistance while restoring carbapenem susceptibility in ST15-KL19 Klebsiella pneumoniae 新型KPC变体KPC-271的鉴定：该变体使ST15-KL19型肺炎克雷伯菌对头孢他啶-阿维巴坦产生耐药性，同时恢复其对碳青霉烯类的敏感性 Hongjian Ou, Siquan Shen, Chengkang Tang, Weiwei Yang, ... Fupin Hu Article 107725 8 Rapid detection of NDM-producing carbapenem-resistant Escherichia coli using MALDI-TOF MS combined with machine learning techniques 基质辅助激光解吸电离飞行时间质谱（MALDI-TOF MS）结合机器学习技术快速检测产新德里金属β-内酰胺酶（NDM）的碳青霉烯类耐药大肠杆菌 Rongrong Dong, Yifei Wang, Lei Song, Jiayin Wang, ... Jiancheng Xu Article 107726 9 Global distribution and genomic architectures of plasmid-mediated quinolone resistance genes in Shigella from 1998 to 2025 1998年至2025年志贺氏菌中质粒介导的喹诺酮类耐药基因的全球分布及基因组结构特征 Juan Geng, Cheng Cheng, Xu Liu, Jinzhao Long, ... Guangcai Duan Article 107737 Short Communications（快报） 10 Global epidemiological trend of Klebsiella pneumoniae ST23: Emergence of KL57 lineage carrying dual carbapenemases 肺炎克雷伯菌ST23型全球流行病学趋势：携带双碳青霉烯酶的KL57谱系的出现 Shuangshuang Li, Guoli Li, Xueqian He, Yawen Yu, ... Zhi Ruan Article 107722 11 Antibiotic susceptibility of Gram-negative bacteria in cerebrospinal fluid compared with Mueller-Hinton broth and artificial cerebrospinal fluid 脑脊液中革兰氏阴性菌对Mueller-Hinton肉汤和人工脑脊液的抗生素敏感性比较 Katrin Biesner, Marija Djukic, Utz Reichard, Roland Nau, Jana Seele Article 107730 Letters to the Editor（致编辑的信） 12 Global, regional, and national burden of multidrug-resistant organisms, 1990–2021 1990 - 2021年全球、区域及国家层面多重耐药菌的疾病负担 Lian Liu, Hong Luo Article 107724 13 Beyond categorical agreement: Antibiotic-specific time to result in rapid susceptibility testing from Gram-negative positive blood cultures 超越分类一致性：针对革兰氏阴性菌血培养阳性的快速药敏试验中不同抗生素的结果检出时间 Tiziana D’Inzeo, Damiano Squitieri, Cataldo Maria Mannavola, Matteo Zelinotti, ... Brunella Posteraro Article 107735 14 Comment on “Phage therapy for KPC-producing Klebsiella pneumoniae de colonisation in high-risk patients: The KIDNAP Study Protocol” 对“针对高危患者中产KPC肺炎克雷伯菌定植的噬菌体疗法：KIDNAP研究方案”的评论 Yinjia Lou, Yiqing Han Article 107733 International Journal of Antimicrobial Agents Volume 67, Issue 5 国际抗微生物制剂杂志 67卷5期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/5 1 Title Page & Editorial Board 目录及编委会 Article 107819 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与资讯页） 2 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与资讯页 Article 107803 Editor's Choice（编辑精选） 3 cirA promoter disruption and SHV-12 production contribute to cefiderocol resistance in carbapenem-resistant Klebsiella pneumoniae cirA启动子破坏与SHV-12酶的产生共同导致碳青霉烯耐药肺炎克雷伯菌对头孢地尔产生耐药性 Fang Shen, Xiaochen Liu, Tailong Lei, Jingjing Quan, ... Qiucheng Shi Article 107756 Hot Topic（热点） 4 Formulating and stabilising therapeutic phages: A review 治疗性噬菌体的配制与稳定化：综述 Eleni Siafakas, Hien T.T. Duong, Jonathan R. Iredell Article 107759 Global Landscape of Phage Therapy（噬菌体疗法的全球概况） 5 Assessing carbonylation in Pseudomonas aeruginosa clinical isolates infected by bacteriophages using flow cytometry 利用流式细胞术评估受噬菌体感染的铜绿假单胞菌临床分离株中的羰基化情况 Jia Hao Yeo, Shuhua Thong, Shimin Jasmine Chung, Andrea Lay-Hoon Kwa Article 107739 AI strategies to combat AMR（应对抗菌药物耐药性的人工智能策略） 6 Causality-informed models for multidrug-resistant organism prediction: Enabling effective ICU antibiotic stewardship 基于因果关系建模的多重耐药菌预测模型：助力重症监护室（ICU）有效开展抗生素管理 Linna Wang, Xinyu Guo, Yimin Chen, Siying Li, ... Li Lu Article 107767 Reviews（综述） 7 Tissue pharmacokinetics of antifungal drugs: a review 抗真菌药物的组织药代动力学：综述 Felix Bergmann, Marlene Prager, Lena Pracher, Anselm Jorda, ... Markus Zeitlinger Article 107743 8 New-generation antibiotics and nonantibiotic strategies against carbapenemase-producing Enterobacterales: More focus on metallo-β-lactamase producers 新一代抗生素及非抗生素策略针对产碳青霉烯酶肠杆菌科细菌：更聚焦于产金属β-内酰胺酶菌种 Shio-Shin Jean, Chih-Cheng Lai, Hou-Tai Chang, Hui-Che Hsiao, ... Po-Ren Hsueh Article 107750 9 A window into resistance: The MEGA-plate as a model of evolutionary dynamics 洞见耐药性：MEGA 培养皿——一种模拟进化动态的模型 Maytham Hussein, Rafah Allobawi, James Barclay, Zhi Ying Kho, ... Tony Velkov Article 107751 Full Length Articles（长篇论著） 10 Efficacy and safety of intracameral amphotericin B for fungal keratitis: A systematic review and meta-analysis 眼内注射两性霉素B治疗真菌性角膜炎的疗效与安全性：一项系统综述与荟萃分析 Kai-Yang Chen, Hoi-Chun Chan, Chi-Ming Chan Article 107707 11 Urine NGAL adds to serum creatinine in predicting cefepime clearance in critically ill children at high risk of acute kidney injury 尿中性粒细胞明胶酶相关脂质运载蛋白（NGAL）联合血清肌酐，可更有效地预测急性肾损伤高风险危重症儿童头孢吡肟的清除率 Horace Rhodes Hambrick, Ronaldo Morales Junior, Calise Curry, Michaela Collins, ... Sonya Tang Girdwood Article 107741 12 Integrative virtual and empirical screening to identify multi-target flavonoid quercetin-3-O-glucuronide for reducing MRSA pathogenicity 通过整合虚拟筛选与实证筛选，确定具有多靶点作用的黄酮类化合物槲皮素-3-O-葡萄糖醛酸苷可降低耐甲氧西林金黄色葡萄球菌（MRSA）的致病性 Hang Gao, Li Wang, Zeze Fu, Yun Sun, ... Yicheng Zhao Article 107744 13 Validation of limited sampling strategies for polymyxin B therapeutic drug monitoring in critical care 重症监护中多粘菌素B治疗药物监测有限采样策略的验证 Yury A. Surovoy, Inna A. Galvidis, Akmal I. Alimov, Sergei V. Tsarenko, Maksim A. Burkin Article 107740 14 Population pharmacokinetics of cefazolin and metronidazole in patients undergoing elective colorectal surgery 择期结直肠手术患者头孢唑林和甲硝唑的群体药代动力学研究 Rochelle Ryan, Scott McDonald, Steven C Wallis, Andre van Zundert, ... Jason A. Roberts Article 107742 15 Omeprazole is associated with voriconazole-associated hepatotoxicity: PPI-stratified analysis and a clinically actionable nomogram from an 848-patient cohort 奥美拉唑与伏立康唑相关肝毒性有关：基于848例患者队列的质子泵抑制剂分层分析及临床可操作的列线图 Yuhang Ding, Yanhong Meng, Huaijun Zhu, Jinping Zhang, Qiuhui Wu Article 107749 16 Treatment sequences of a phage and colistin combination trigger different evolution pathways of a multidrug-resistant Acinetobacter baumannii yielding distinct treatment outcomes 噬菌体与粘菌素（多粘菌素E）联合用药的不同治疗顺序可引发多重耐药鲍曼不动杆菌的不同进化路径，进而产生截然不同的治疗效果 Subhankar Mukhopadhyay, Xiaoxu Zhang, Kenneth K.W. To, Yannan Liu, ... Sharon S.Y. Leung Article 107745 17 L-Cycloserine, not d-Cycloserine, inhibits IscS-mediated iron–sulfur cluster biosynthesis in Escherichia coli L-环丝氨酸（而非D-环丝氨酸）抑制大肠杆菌中由IscS介导的铁硫簇生物合成 Lihe Zhang, Yongjuan Li, Yuhang Bao, Jie Feng, ... Wu Wang Article 107761 18 Molecular mechanisms and clonal distribution of cefiderocol-resistant blaNDM-carrying Escherichia coli: A multi-centre study in China 携带产头孢他啶/阿维巴坦耐药基因blaNDM的大肠杆菌的分子机制及克隆分布：中国多中心研究 Chengkang Tang, Siquan Shen, Renru Han, Dandan Yin, ... Fupin Hu Article 107762 Short Communications（短讯） 19 Present trajectories to forecasted future: A longitudinal analysis of hospital antibiotic use in China from 2013 to 2024 and projections to 2030 现状轨迹至预测未来：2013 年至 2024 年中国医院抗生素使用情况的纵向分析及至 2030 年的预测 Weibin Li, Fenqi Du, Ruowei Xiao, Weihsin Ko, ... Haishaerjiang Wushouer Article 107764 Letters to the Editor（致编辑的信） 20 Comment on ‘Pharmacokinetics of ampicillin, sulbactam, and combined ampicillin/sulbactam in subcutis, muscle, and plasma: A microdialysis trial in healthy volunteers’ 对“氨苄西林、舒巴坦及氨苄西林/舒巴坦联合用药在皮下组织、肌肉和血浆中的药代动力学：一项在健康志愿者中进行的微透析试验”的评论 Kishankumar Mahida, Snehal Rajendra Jagtap Article 107736 21 Comment on: “Therapeutic drug monitoring of isavuconazole: Trends and update” 述评：“艾沙康唑治疗药物监测：趋势与最新进展” Zhibin Xu, Shouning Zhou, Lulin Wang, Xiaohua Wang, ... Chunrong Ju Article 107732 22 Comprehensive analysis of 16S rRNA methyltransferases in Enterobacterales isolated from dogs and cats reveals co-resistance with broad-spectrum β-lactamases 对从猫狗体内分离出的肠杆菌目细菌中16S rRNA甲基转移酶的全面分析揭示其与广谱β-内酰胺酶共存耐药性 Fábio Parra Sellera, Yawen Yu, Yingying Zhang, Luciana Sartori, ... João Pedro Rueda Furlan Article 107747 23 Comment on "Effect of probiotic strain, duration, and dose on preventing ICU-acquired infection: A scoping review" 评论：“益生菌菌株、疗程和剂量对预防重症监护病房获得性感染的影响：一项范围综述” Jiayi Yu Article 107758 24 Comment on “Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis” 对《肾盂肾炎及复杂性尿路感染治疗中不同类别抗生素的比较：一项系统综述与荟萃分析》一文的评论 Qiao Chen Article 107770 Corrigendum（勘误表） 25 Corrigendum to “Phage therapy for KPC-producing Klebsiella pneumoniae decolonization in high-risk patients: The KIDNAP Study Protocol - A prospective feasibility and proof of concept study in the Brazilian context” [International Journal of Antimicrobial Agents Volume 67(2026)107673] 对“针对产KPC酶肺炎克雷伯菌定植清除的高危患者实施噬菌体治疗：《KIDNAP研究方案》——巴西背景下的一项前瞻性可行性及概念验证研究”[《国际抗微生物制剂杂志》第67卷（2026年）第107673篇]的勘误 Iris Najjar, Larissa Simão Gandolpho, Jôiciglecia Pereira dos Santos, Camila de Paula Siqueira, ... Ana C. Gales Article 107766

2026-05-07

·动脉网

Edgewise Therapeutics报告2026年第一季度财务业绩并推进肌肉萎缩症和心血管适应症的临床项目

– –Announced positive long-term sevasemten data demonstrating sustained functional stabilization in Becker muscular dystrophy (Becker) up to 3.5 years of follow-up – 宣布了积极的长期sevasemten数据，显示在贝克尔肌营养不良症（Becker）中长达3.5年的随访中持续的功能稳定——– –CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in Q2 2026 – CIRRUS-HCM 12周数据：EDG-7500用于梗阻性和非梗阻性肥厚型心肌病（HCM），预计将于2026年第二季度发布。– –Pivotal GRAND CANYON results for sevasemten in Becker expected in Q4 2026 2026年第四季度预计将迎来贝克尔Sevasemten的关键GRAND CANYON结果– –BOULDER, Colo. 科罗拉多州博尔德, ，May 7, 2026 2026年5月7日/PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: /PRNewswire/ -- Edgewise Therapeutics, Inc. (纳斯达克:EWTX EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2026 and recent business highlights ），一家领先的肌肉疾病生物制药公司，今天报告了2026年第一季度的财务结果和最近的业务亮点。. 。'For the first time with an investigational agent, we have generated long-term data showing that people with Becker remain stable despite a disease that typically leads to significant functional decline,' said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. 'We remain on track to report pivotal top-line data from GRAND CANYON evaluating sevasemten, which has the potential to support our first marketing application in Becker. “我们首次使用一种研究性药物，生成了长期数据，表明贝克尔患者尽管通常会导致显著的功能衰退，但仍然保持稳定，”Edgewise 总裁兼首席执行官 Kevin Koch 博士说道。“我们正按计划报告 GRAND CANYON 评估 sevasemten 的关键主要数据，这有可能支持我们在贝克尔症上的首个上市申请。”We also anticipate results this quarter from CIRRUS-HCM 12-week Part D evaluating EDG-7500 in HCM, which will help refine our Phase 3 strategy. With multiple near-term catalysts and a highly focused team, we are well positioned to advance our programs and deliver potentially transformative therapeutic options for patients facing serious muscle diseases facing high unmet need.'. 我们还预计本季度将从CIRRUS-HCM的12周D部分获得评估EDG-7500在肥厚型心肌病（HCM）中的结果，这将有助于完善我们的第三阶段策略。凭借多个短期催化剂和高度专注的团队，我们有能力推进我们的项目，并为面临严重肌肉疾病且未满足需求高的患者提供可能具有变革性的治疗选择。Recent Highlights 近期亮点 Muscular Dystrophy Program 肌肉萎缩症项目MESA open-label extension trial in adults with Becker: MESA 开放标签扩展试验，针对贝克尔型肌营养不良症成人患者：MESA is an open-label extension study evaluating sevasemten long-term safety, tolerability, and efficacy in adults and adolescents with Becker previously treated in sevasemten clinical trials. Nearly all eligible participants (99%) from prior sevasemten studies (including ARCH, DUNE and CANYON/GRAND CANYON) chose to enroll in the MESA open-label extension study.. MESA 是一项开放标签扩展研究，评估塞伐森坦在先前参与塞伐森坦临床试验的贝克尔病成人和青少年中的长期安全性、耐受性和有效性。几乎所有符合条件的参与者（99%）来自之前的塞伐森坦研究（包括 ARCH、DUNE 和 CANYON/GRAND CANYON），选择加入 MESA 开放标签扩展研究。At the 2026 MDA Clinical and Scientific Conference, the Company presented long-term data from MESA showing participants on sevasemten experienced stabilization of function up to 3.5 years in marked contrast to the functional decline expected from Becker natural history data. The data reinforce prior clinical findings of sevasemten in Becker, a rare disease with no approved treatments. 在2026年MDA临床与科学会议上，该公司展示了来自MESA的长期数据，显示接受sevasemten治疗的参与者功能稳定长达3.5年，这与贝克尔肌营养不良自然病史数据中预期的功能下降形成鲜明对比。这些数据进一步验证了sevasemten在贝克尔肌营养不良中的先前临床研究结果，这是一种尚无获批治疗方法的罕见疾病。The results can be found . 结果可以找到。here 这里. The Company also presented a poster with new analysis from the CANYON study showing sevasemten had a well-tolerated cardiac profile over 12 months, with no adverse effects on left ventricular ejection fraction (LVEF) or NT‑proBNP and evidence of LVEF improvement in certain subgroups, with positive trends observed across all adult participants versus placebo. 公司还展示了一张海报，其中包含了来自CANYON研究的新分析，显示sevasemten在12个月内具有良好的心脏耐受性，对左心室射血分数（LVEF）或NT-proBNP没有不良影响，并且在某些亚组中观察到LVEF改善的证据，所有成年参与者相对于安慰剂均显示出积极趋势。The poster can be viewed . 海报可以查看。here 这里. To learn more about MESA or CANYON, go to clinicaltrials.gov (MESA: 要了解更多关于MESA或CANYON的信息，请访问clinicaltrials.gov（MESA：NCT06066580 NCT06066580, CANYON ( ，峡谷（NCT05291091 NCT05291091). ）。GRAND CANYON, a global pivotal placebo-controlled cohort in Becker: 大峡谷，贝克尔全球关键的安慰剂对照队列： GRAND CANYON is designed to assess the efficacy and safety of sevasemten over an 18-month period, with North Star Ambulatory Assessment (NSAA) as the primary endpoint. The study is highly powered to be able to show a statistically significant difference in NSAA versus placebo over 18 months. The Company expects to report top-line data in the fourth quarter of 2026 and is continuing preparations for a potential marketing application to seek approval as the first targeted therapy for this underserved population, planned for the first half of 2027. GRAND CANYON 旨在评估 sevasemten 在 18 个月期间的疗效和安全性，其主要终点为北极星移动能力评估（NSAA）。该研究具备高度统计效力，能够在 18 个月内显示出 NSAA 相较于安慰剂的统计学显著差异。公司预计将在 2026 年第四季度公布初步数据，并继续为潜在的上市申请做准备，目标是寻求在 2027 年上半年将该药物作为首个针对这一未满足需求人群的靶向疗法获批。To learn more about GRAND CANYON, go to clinicaltrials.gov (. 要了解更多关于大峡谷的信息，请访问clinicaltrials.gov。NCT05291091 NCT05291091). ）。 LYNX and FOX Phase 2 placebo-controlled trials in boys with Duchenne: LYNX 和 FOX 第二阶段安慰剂对照试验，针对患有杜氏肌营养不良症的男孩：LYNX is designed to evaluate the effect of sevasemten on safety, biomarkers of muscle damage and function in boys with Duchenne in a placebo-controlled dose ranging study, followed by an open-label extension period. FOX is designed to evaluate the effect of sevasemten on safety, biomarkers of muscle damage and function in children and adolescents with Duchenne who have been previously treated with gene therapy. LYNX 旨在评估sevasemten在安慰剂对照的剂量范围研究中对杜氏肌营养不良男孩的安全性、肌肉损伤和功能的生物标志物的影响，随后是一个开放标签的延长期。FOX 旨在评估sevasemten在之前接受过基因治疗的杜氏肌营养不良儿童和青少年中的安全性、肌肉损伤和功能的生物标志物的影响。The Company continues to collect longer-term data in the open-label extension portion of these Phase 2 programs to inform the future clinical studies in Duchenne. For more information, go to clinicaltrials.gov to learn more about LYNX (. 公司继续在这些二期项目的开放标签扩展部分收集长期数据，以告知未来在杜氏肌营养不良症中的临床研究。欲了解更多信息，请访问 clinicaltrials.gov 了解更多关于 LYNX 的信息。NCT05540860 NCT05540860) and FOX ( ）和FOX（NCT06100887 NCT06100887). ）。Cardiovascular Programs 心血管项目CIRRUS-HCM Phase 2 trial in adults with symptomatic HCM: CIRRUS-HCM 第2阶段试验，针对有症状的成人HCM患者：The Company is advancing CIRRUS-HCM, a multi-part, open-label trial, in participants with HCM at over 20 clinical sites in the U.S. Part A of the trial evaluated the safety and tolerability of a single oral dose of EDG-7500 in participants with obstructive HCM (oHCM). Parts B and C evaluated fixed doses of EDG-7500 over 28 days in oHCM and nonobstructive HCM (nHCM), respectively. 公司正在美国超过20个临床试验点推进CIRRUS-HCM，这是一项多部分、开放标签的试验，针对肥厚型心肌病（HCM）患者。试验的A部分评估了单次口服EDG-7500在梗阻性肥厚型心肌病（oHCM）患者中的安全性和耐受性。B部分和C部分分别评估了EDG-7500固定剂量在oHCM和非梗阻性肥厚型心肌病（nHCM）患者中持续28天的效果。The results can be found . 结果可以找到。here 这里. Part D is a 12-week study with an open-label extension including participants with oHCM and nHCM designed to explore dose response and optimization. The Company plans to report 12-week Part D data (oHCM and nHCM) in the second quarter of 2026 and initiate Phase 3 in the second half of 2026. To learn more about CIRRUS-HCM, visit clinicaltrials.gov, . 第D部分是一项为期12周的开放标签扩展研究，包括oHCM和nHCM患者，旨在探索剂量反应和优化。公司计划在2026年第二季度报告第D部分12周的数据（oHCM和nHCM），并在2026年下半年启动第三阶段。要了解有关CIRRUS-HCM的更多信息，请访问clinicaltrials.gov。NCT06347159 NCT06347159. 。EDG-15400 and heart failure: EDG-15400 与心力衰竭：EDG-15400 is a novel oral, selective, cardiac sarcomere modulator, targeted for the treatment of heart failure and other diseases of diastolic dysfunction. EDG-15400 is currently being evaluated in healthy adults in a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics. EDG-15400 是一种新型的口服、选择性心脏肌节调节剂，旨在治疗心力衰竭和舒张功能障碍相关疾病。目前，EDG-15400 正在健康成人中进行一项一期随机、双盲、安慰剂对照的单次和多次递增剂量研究，以评估其安全性、耐受性、药代动力学和药效学。The Company expects to initiate a Phase 2 trial in participants with heart failure with preserved ejection fraction (HFpEF) in the second half of 2026. To learn more about this study, go to clinicaltrials.gov (. 公司预计将在2026年下半年启动针对射血分数保留的心力衰竭（HFpEF）患者的二期试验。如需了解更多关于本研究的信息，请访问clinicaltrials.gov。NCT07177066 NCT07177066). ）。 First Quarter 2026 Financial Results 2026年第一季度财务业绩Cash, cash equivalents and marketable securities 现金、现金等价物和可出售证券were approximately $499.6 million as of March 31, 2026. 截至2026年3月31日，约为4.996亿美元。Research and development (R&D) expenses 研发费用were $42.7 million for the first quarter of 2026, compared to $36.8 million for the same period in 2025. The increase was primarily driven by increased clinical development activity related to EDG‑7500 and EDG‑15400, as well as higher internal personnel‑related costs to support the advancement of the Company's clinical‑stage programs. 2026年第一季度为4,270万美元，而2025年同期为3,680万美元。增长的主要原因是与EDG-7500和EDG-15400相关的临床开发活动增加，以及支持公司临床阶段项目进展的内部人员相关成本上升。These increases were partially offset by lower sevasemten clinical program expenses due to timing of activity in the GRAND CANYON study and patient rollover into the MESA open‑label extension study.. 这些增长部分被塞瓦森临床项目费用的减少所抵消，原因是大峡谷研究活动的时间安排以及患者转入MESA开放标签扩展研究。General and Administrative (G&A) expenses 一般及行政（G&A）费用were $11.5 million for the first quarter of 2026, compared to $9.2 million for the same period in 2025. The increase was primarily due to higher personnel‑related costs, including stock‑based compensation, as the Company expanded its organizational capabilities to support clinical development, as well as increased professional fees and other administrative costs.. 2026年第一季度为1,150万美元，而2025年同期为920万美元。增长的主要原因是人员相关成本增加，包括基于股票的薪酬，因为公司扩展了其组织能力以支持临床开发，同时专业费用和其他管理成本也有所增加。Net loss and net loss per share 净亏损和每股净亏损were $49.0 million or $0.46 per share for the first quarter of 2026, compared to $40.8 million or $0.43 per share for the same period in 2025. 2026年第一季度为4900万美元，即每股0.46美元，而2025年同期为4080万美元，即每股0.43美元。About Edgewise Therapeutics 关于Edgewise TherapeuticsEdgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Edgewise Therapeutics是一家领先的肌肉疾病生物制药公司，专注于开发针对肌肉萎缩症和严重心脏疾病的新型疗法。公司在肌肉生理学方面的深厚专业知识推动了新一代创新治疗药物的发展。Sevasemten是一种口服的首创快速骨骼肌肌球蛋白抑制剂，目前正处于贝克尔和杜氏肌肉萎缩症的晚期临床试验阶段。EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases.To learn more, go to . EDG-7500 是一种新型的心脏肌节调节剂，用于治疗症状性肥厚型心肌病，目前处于二期临床开发阶段。EDG-15400 是一种新型的心脏肌节调节剂，用于治疗心力衰竭，目前处于一期临床开发阶段。Edgewise 的全体团队致力于我们的使命：改变受严重肌肉疾病影响的患者及其家庭的生活。欲了解更多信息，请访问。edgewisetx.com edgewisetx.comor follow us on 或关注我们LinkedIn 领英, ，X X, ，Facebook Facebookand 和Instagram 图片分享社交平台 . 。Cautionary Note Regarding Forward-Looking Statements 关于前瞻性陈述的警告性说明This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, Edgewise's product candidates and programs, including sevasemten, EDG-7500, EDG-15400 and its cardiovascular programs; statements regarding Edgewise's expectations relating to its clinical trials, including timing of reporting data (including 12-week data on the CIRRUS-HCM trial, and the data from the GRAND CANYON trial; statements regarding Edgewise's potential marketing application in Becker; statements regarding sevasemten potentially being the first approved therapy for Becker; statements regarding the potential results of Edgewise's GRAND CANYON trial; statements regarding Edgewise's market opportunity; statements regarding Edgewise's plans to continue to collect longer-term open-label extension data for its LYNX and FOX Phase 2 trials; statements regarding timing of Edgewise's initiation of a Phase 3 trial of EDG-7500 in HCM and a Phase 2 trial of EDG-15400 in participants with HFpEF; statements regarding Edgewise's ability to advance its pipeline; and statements by Edgewise's President and Chief Executive Officer. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'intends,' 'will,' 'goal,' 'potential' and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon Edgewise's current expectations and involve assumptions that may never materialize or may prove to be incorrect. 本新闻稿包含1933年《证券法》第27A条和1934年《证券交易法》第21E条所定义的前瞻性陈述。本新闻稿中的非纯粹历史性的陈述为前瞻性陈述。这些前瞻性陈述包括但不限于关于Edgewise的产品候选药物和项目的潜力及预期的陈述，包括sevasemten、EDG-7500、EDG-15400及其心血管项目；关于Edgewise对其临床试验的预期陈述，包括数据报告的时间（包括CIRRUS-HCM试验的12周数据和GRAND CANYON试验的数据）；关于Edgewise在贝克尔病中潜在的市场应用陈述；关于sevasemten可能成为贝克尔病首个获批疗法的陈述；关于Edgewise的GRAND CANYON试验潜在结果的陈述；关于Edgewise市场机会的陈述；关于Edgewise计划继续收集LYNX和FOX 2期试验长期开放标签扩展数据的陈述；关于EDG-7500在肥厚型心肌病（HCM）中启动3期试验和EDG-15400在HFpEF患者中启动2期试验时间的陈述；关于Edgewise推进其产品管线能力的陈述；以及Edgewise总裁兼首席执行官的陈述。诸如“相信”、“预期”、“计划”、“预计”、“意图”、“将”、“目标”、“潜力”等词汇及类似表达旨在识别前瞻性陈述。此处包含的前瞻性陈述基于Edgewise的当前预期，并涉及可能永远不会实现或可能被证明为不正确的假设。. 。. 。This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release. 本新闻稿包含指向未被视为并入本新闻稿参考的信息的超链接。Edgewise Therapeutics, Inc. 边缘疗法公司 Condensed Statement of Operations 综合损益表(in thousands except share and per share amounts, unaudited) （除股份和每股金额外，单位为千，未经审计）Three months ended 三个月末March 31, 2026 2026年3月31日March 31, 2025 2025年3月31日Operating expenses: 营业费用：Research and development 研究与开发$ $42,651 42,651$ $36,757 36,757General and administrative 一般和行政管理11,464 11,4649,202 9,202Total operating expenses 营业总费用54,115 54,11545,959 45,959Loss from operations 营业亏损(54,115) (54,115)(45,959) （45,959）Interest income 利息收入5,102 5,1025,161 5,161Net loss 净亏损$ $(49,013) （49,013）$ $(40,798) （40,798）Net loss per share - basic and diluted 每股净亏损 - 基本和稀释$ $(0.46) (0.46)$ $(0.43) (0.43)Weighted-average shares outstanding, basic and diluted 加权平均流通股数，基本和稀释107,116,709 107,116,70995,130,053 95,130,053Edgewise Therapeutics, Inc. Edgewise Therapeutics, Inc.Condensed Balance Sheet Data 简明资产负债表数据(in thousands, unaudited) （单位：千，未经审计）March 31, 3月31日，December 31, 12月31日，2026 20262025 2025Assets 资产Cash, cash equivalents and marketable securities 现金、现金等价物和可出售证券$ $499,562 499,562$ $530,109 530,109Other assets 其他资产18,960 18,96022,494 22,494Total assets 总资产$ $518,522 518,522$ $552,603 552,603Liabilities and stockholders' equity 负债和股东权益Liabilities 负债25,319 25,31930,346 30,346Stockholders' equity 股东权益493,203 493,203522,257 522,257Total liabilities and stockholders' equity 总资产负债和股东权益$ $518,522 518,522$ $552,603 552,603SOURCE Edgewise Therapeutics 来源：Edgewise Therapeutics21 21% %more press release views with 更多新闻发布视图与 Request a Demo 请求演示

2026-05-06

·QQ浏览器

12635个原子！量子计算摸到蛋白质了吗？

量子计算正在从小分子演示，进入与超级计算共同处理真实生物体系的工程阶段。蛋白质像一座折叠的城市。每一个原子都是灯点，电子在灯点之间移动，药物分子只有找到恰当的缝隙，才可能改变一条生命通路。量子计算谈医药已经谈了很多年，但很长一段时间里，它更像远处的灯塔：方向清楚，距离模糊。5月5日，IBM、RIKEN和克利夫兰诊所把这盏灯往前推了一段。三方宣布，研究团队用量子中心超级计算方法模拟了一个由12635个原子组成的蛋白质-配体复合物，IBM称其为“已知最大规模的量子计算蛋白质模拟”。与其说这是一场关于单台量子计算机的胜利，不如说它展示了量子处理器、算法、超算与生命科学问题第一次以更接近真实任务的方式扣在一起。这不是“量子优势”的宣布，也不是药物研发被一夜改写。它更像一个清晰信号：量子计算正在从小分子演示，进入与超级计算共同处理真实生物体系的工程阶段。指数之墙与生物医学的算力危机在当代制药工业的宏大叙事中，寻找一种能够精准锁定蛋白靶点的药物分子，无异于在银河系中寻找一颗特定的尘埃。蛋白质作为生命功能的执行者，其结构之复杂、动态之微妙，使得传统的计算化学方法在它们面前显得捉肘见襟。计算化学的核心困境在于求解多电子系统的薛定谔方程。虽然方程的形式在物理学家眼中简洁优美，但在处理生物大分子时，其计算量会随着系统规模的增加而呈指数级增长。每一个电子不仅受到原子核的吸引，还受到其他所有电子的排斥和相互关联，这种被称为“电子关联”的现象是化学反应和分子结合的本质。目前主流的经典计算方法在处理这些问题时面临着严重的权衡：密度泛函理论（DFT）虽然能够处理成千上万个原子，但它依赖于近似，往往难以准确捕捉药物分子与蛋白之间关键的弱相互作用；而被称为“金标准”的耦合簇方法（CCSD）虽然精度极高，但其计算复杂度随轨道数量的七次方增长，这使其只能处理几十个原子的微小系统。这种算力的匮乏直接导致了药物研发的时间博弈。由于无法在模拟中获得足够的精度，制药公司不得不依赖昂贵的物理实验和反复的临床测试。目前，开发一种新药平均需要耗费超过10年的时间，投资额高达数十亿美元。如果能够利用量子计算的特性，在计算机中准确预测候选药物与蛋白质的结合亲和力，将极大地缩短研发周期，为人类对抗致命疾病赢得宝贵时间。 12000原子的跨代跃迁2026年5月5日，科学界迎来了一个分水岭时刻。克利夫兰医学中心、日本理化学研究所与IBM联合发布的研究成果显示，他们利用量子处理器与全球最强大的超级计算机协同工作，完成了对包含12635个原子的蛋白质复合体的高精度模拟。这一成果不仅刷新了量子计算模拟生物分子的规模纪录，更证明了量子计算机在当前的“效用阶段”已经具备了解决实际科学问题的能力。研究团队并未选择结构简单的实验分子，而是选择了具有重大医疗价值的系统：胰蛋白酶和T4溶菌酶。胰蛋白酶是人体消化系统中不可或缺的酶，而T4溶菌酶则是免疫系统对抗细菌入侵的关键。更重要的是，这些系统被置于真实的液态水溶液环境中进行模拟，而非真空的孤立状态。来源：IBM在数月前，同类研究的模拟规模还仅限于303个原子的Trp-cage微蛋白。在半年内实现40倍的规模飞跃，其背后的技术驱动力令人惊叹。这项任务动用了跨越国界的顶级算力资源：位于美国克利夫兰和日本神户的两台156量子比特IBM Quantum Heron r2处理器，以及日本的“富岳”（Fugaku）超算和Miyabi-G超算系统。在大约100小时的连续运行中，系统执行了9200个量子电路，收集了多达13亿次的测量结果。这是迄今为止量子化学领域资源投入最为密集、计算规模最为宏大的异构计算实验。量子中心超级计算为了实现这种海量原子的模拟，单纯增加量子比特的数量是不够的。IBM提出的“量子中心超级计算”（QCSC）框架提供了一种全新的范式，将量子计算机作为高性能计算工作流中的核心加速单元，而非独立的孤岛。这种QCSC架构打破了量子计算与经典计算之间的界限。在这一框架下，硬件基础设施被划分为多个层级：第一层是负责实时操作和纠错解码的量子系统；第二层是与之紧密相连的CPU和GPU系统，用于低延迟的任务管理；第三层则是远程的大规模超算集群，负责处理海量的数据拼接。来源：IBM在模拟12635个原子的胰蛋白酶时，传统的“串行”模式——即量子算完再传给经典——会导致严重的效率瓶颈。QCSC架构实现了闭环的数据交换，使得量子处理器（QPU）能够像经典CPU访问缓存一样，高效地参与到整个迭代计算中。日本理化学研究所的“富岳”超算拥有超过15万个计算节点，其惊人的并行处理能力与量子处理器的采样能力相结合，实现了72.5%的并行效率。这种紧密的编排证明，量子与经典并非竞争对手，而是可以完美合奏的伙伴。EWF-TrimSQD的精妙逻辑如果没有算法上的突破，即便拥有最强大的硬件，也无法在有限的时间内处理1.2万个原子的电子纠缠。研究团队开发的EWF-TrimSQD算法结合了“分而治之”的数学思想与量子物理的深刻洞察。首先是波函数嵌入技术（EWF）。算法基于一个深刻的物理前提：在大多数蛋白质系统中，电子的强关联效应具有局域性，一个原子的电子行为主要受到其周围7-10埃范围内环境的影响。通过将巨大的蛋白质复合体分解为成千上万个相互重叠的小碎片，算法将整体计算的复杂度降低到了线性阶次。对于大多数简单的碎片，系统使用经典方法处理；而对于涉及药物结合位点的关键核心，则交给QPU进行高精度模拟。来源：IBM接下来的关键是采样量子对角化（SQD）。电子构型空间是一个组合爆炸的汪洋大海，而真正决定能量稳定的构型只是极小部分。理论化学家Klaus Ruedenberg曾用“活木”和“死木”来形容这种差异：在海量的构型中，超过99%是毫无意义的“死木”。量子计算机通过SQD算法，像是在海量的拼图碎片中迅速找出了构成画面核心的那几块“活木”，而经典超算随后在这些精选出的碎片基础上完成最后的拼图。这种“修剪”机制将计算精度提升了210倍，使得结果能够与经典计算的最高标准相媲美。从效用到容错的远征虽然12635个原子的模拟已是壮举，但这仅仅是量子计算星辰大海的起点。根据IBM更新的路线图，我们正站在通往“容错量子计算”的关键节点上。2025年，名为“Loon”的处理器将测试新型纠错码，旨在将纠错成本降低90%；2026年，“Kookaburra”将引入模块化架构，让量子信息在芯片间自由流动。而所有的目光都锁定了2029年，届时IBM计划推出首个大规模容错系统“Starling”。Starling将拥有200个逻辑量子比特，能够执行1亿个量子门操作。这意味着到那时，我们或许不再需要将分子拆解成碎片，而是可以直接对整个蛋白质核心进行无损的量子重构。来源：IBM更令人振奋的是量子计算与人工智能的汇流。正如IBM首席执行官Arvind Krishna所指出的，量子计算负责生成极其精确的微观能量数据，而AI则学习这些数据中的模式。这种协同将彻底改写新材料和新药物的发现规则：量子提供真理的深度，AI提供探索的广度。量子计算正在从“能跑”转向“能嵌入”过去几年，量子计算的新闻多围绕硬件指标展开：量子比特数、门错误率、相干时间、纠错码距、逻辑错误率。它们仍然重要，但这次新闻给出的信号更偏应用侧：一个有真实科学意义的问题，如何被拆成可交给量子处理器和超算共同完成的作业？如何在不同硬件之间调度？如何把量子采样变成经典求解的有效输入？如何让结果能被化学家和药物研究者理解？这种转向也会改变企业和科研机构评估量子计算的方式。过去看一台量子计算机，常问它有多少量子比特、线路保真度多高；未来还要问它能否稳定接入超算调度，能否支持长时间作业，能否与经典化学软件、数据格式、误差分析和任务管理系统衔接。对真实用户来说，可用性往往不只来自芯片，而来自整条链路。如果说早期NISQ阶段的许多演示是在证明“量子设备确实能运行”，那么这类工作开始证明“量子设备可以嵌入科学计算基础设施”。这也是它对产业判断的价值所在。近期量子计算最值得关注的方向，并不只是单机性能竞赛，而是量子处理器、GPU/CPU超算、低时延控制、软件栈和具体科学任务之间的耦合能力。谁能把这些环节接成稳定流水线，谁就更接近可用量子算力。还不能过度乐观，但也不该低估当算力不再是制约认知的障碍，人类对生命的掌控将达到前所未有的高度。这项技术突破最直接的影响在于个性化医疗的普及。未来，我们可以根据每个人的基因特征，在量子空间中预演药物的相互作用，实现真正的“精准打击”。在下一次突发流行病侵袭时，量子中心超级计算机可以在数周内完成对病毒蛋白的扫描，筛选出最佳候选药物，而非被动地等待实验结果。冷静地看，这次实验距离药物研发的日常可用仍有几道门槛。精度要提高，基组要更接近真实化学需求，误差缓解和片段策略要更稳，量子硬件要更低错误率、更高可用性，整条工作流还要从论文级演示走向可重复、可计费、可维护的平台服务。即便如此，它仍然值得被认真记录。原因很简单：量子计算的进步从来不是一夜之间替代经典计算，而是先在经典计算最吃力的角落打开缝隙。目前，量子计算还没有成为药物发现的发动机。它更像是被接入一台巨大的科研机器中的新部件，第一次在真实生物体系的尺度上发出稳定的声响。今天我们听到的不是终点的礼炮，而是车间里一枚齿轮开始咬合的声音。对于量子计算来说，这也许正是更重要的开始。参考链接[1]https://newsroom.ibm.com/2026-05-05-cleveland-clinic,-riken,-and-ibm-model-a-12,635-atom-protein-the-largest-known-to-be-simulated-with-quantum-computers[2]https://arxiv.org/abs/2605.01138[3]https://www.ibm.com/quantum/blog/cleveland-clinic-protein-qcsc[4]https://www.ibm.com/quantum/blog/cleveland-clinic-riken-chemistry[5]https://research.ibm.com/blog/quantum-centric-supercomputing-system-reference-architecture

100 项与西妥木单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09328	西妥木单抗	-	DB12250

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肺泡软组织肉瘤	临床2期	美国	National Cancer Institute	2012-06-18
肺泡软组织肉瘤	临床2期	加拿大	National Cancer Institute	2012-06-18
尤文肉瘤	临床2期	美国	National Cancer Institute	2012-06-18
尤文肉瘤	临床2期	加拿大	National Cancer Institute	2012-06-18
神经胶质肉瘤	临床2期	美国	National Cancer Institute	2012-06-18
神经胶质肉瘤	临床2期	加拿大	National Cancer Institute	2012-06-18
血管肉瘤	临床2期	美国	National Cancer Institute	2012-06-18
血管肉瘤	临床2期	加拿大	National Cancer Institute	2012-06-18
脂肪肉瘤	临床2期	美国	National Cancer Institute	2012-06-18
脂肪肉瘤	临床2期	加拿大	National Cancer Institute	2012-06-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01413191 (Pubmed \| Melanoma Res) 人工标引	临床2期	葡萄膜黑色素瘤	18	imc-a12	糧壓齋齋醖製壓衊製網(窪淵窪艱構鬱觸鏇觸衊) = 選夢範鏇壓淵鹽網願膚糧窪窪繭廠顧遞壓艱憲 (醖夢選遞觸襯築膚築醖 ) 更多	不佳	2020-12-01
NCT01026623 (Pubmed \| Clin Genitourin Cancer) 人工标引	临床1期	转移性去势抵抗性前列腺癌	16	cixutumumab+Temsirolimus (cohort 1)	積積夢衊觸獵鑰顧鹽艱(鬱淵製衊構糧衊醖艱鏇) = The most common adverse events included hyperglycemia (100%; 31% grade 3), oral mucositis (63%; 19% grade 3), and diarrhea (44%; 0 grade 3). Low-grade pneumonitis occurred in 7 of 11 patients (44%; 0 grade 3). 醖願構遞餘簾範窪鹽構 (觸簾糧醖襯夢願膚衊醖 ) 更多	不佳	2020-06-01
				cixutumumab+Temsirolimus (cohort -1)
NCT00957853 (CTgov)	临床2期	头颈部鳞状细胞癌 \| 头颈部皮肤鳞状细胞癌	16	Cetuximab (Cetuximab)	壓壓遞鏇衊構醖壓鬱艱 = 壓獵鬱願餘積襯艱鏇艱窪衊範餘獵膚選艱餘餘 (壓淵鏇鬱糧憲艱鹹製鏇, 窪築獵餘鏇築鹽餘構觸 ~ 構夢顧襯鹽鹽餘淵網壓) 更多	-	2020-03-19
				IMC-A12 (IMC-A12)	壓壓遞鏇衊構醖壓鬱艱 = 廠獵範願鹽獵選鹹範顧窪衊範餘獵膚選艱餘餘 (壓淵鏇鬱糧憲艱鹹製鏇, 襯遞憲齋艱膚醖顧膚齋 ~ 壓製獵網願醖窪顧鏇襯) 更多
NCT01120236 (SWOG S0925, ASCO_GU2020)	临床2期	去势抵抗性前列腺癌	210	Androgen deprivation + cixutumumab	夢餘積範廠餘齋築選蓋(醖糧遞鹽鹹廠鬱鏇製憲): HR = 1.01 (95% CI, 0.7 ~ 1.45), P-Value = 0.97 更多	不佳	2020-02-19
				Androgen deprivation
NCT01026623 (CTgov)	临床1/2期	复发性前列腺癌 \| 去势抵抗性前列腺癌 \| 转移性前列腺癌 ... 更多	16	IMC-A12+Temsirolimus (IMC-A12: 6 mg/kg Temsirolimus 20 mg)	廠構窪鬱艱壓網廠鏇積 = 遞壓構鬱衊淵衊鹹憲築網鬱簾繭鏇鬱範壓遞鏇 (鑰夢鬱蓋構繭構糧製膚, 壓範繭廠繭鏇窪醖廠壓 ~ 襯蓋襯遞鏇膚獵願鏇願) 更多	-	2019-06-17
				IMC-A12+Temsirolimus (IMC-A12: 6 mg/kg Temsirolimus 25 mg)	廠構窪鬱艱壓網廠鏇積 = 鬱衊獵鬱繭衊夢襯願憲網鬱簾繭鏇鬱範壓遞鏇 (鑰夢鬱蓋構繭構糧製膚, 獵壓選夢網鹽選網壓壓 ~ 膚構廠膚廠壓糧鬱鹽鹽) 更多
NCT01263782 (CTgov)	临床2期	晚期非小细胞肺癌	64	Carboplatin+Pemetrexed (Carboplatin + Pemetrexed x 4 Cycles Followed by Maintenance Pe)	淵遞顧範網淵選糧鹹廠(淵壓鹹網觸構醖範鬱積) = 膚製衊鹹蓋衊構鬱選範積窪壓繭餘鏇衊夢構積 (顧艱淵繭餘觸淵簾憲獵, 壓餘繭醖積構窪築齋艱 ~ 簾顧襯顧餘網鏇鹹鹹鑰) 更多	-	2019-05-08
				Carboplatin+Pemetrexed+Bevacizumab (Carboplatin + Pemetrexed + Bevacizumab Followed by Maintenance)	淵遞顧範網淵選糧鹹廠(淵壓鹹網觸構醖範鬱積) = 觸積鏇選範積獵鹽膚醖積窪壓繭餘鏇衊夢構積 (顧艱淵繭餘觸淵簾憲獵, 襯範積壓餘憲鏇觸繭繭 ~ 範蓋繭衊膚範鬱鏇艱憲) 更多
NCT01007032 (CTgov)	临床1期	晚期恶性实体瘤	21	Cixutumumab (Cixutumumab Cohort 1)	構醖膚膚鹽網糧餘廠憲 = 壓醖蓋壓遞齋淵繭繭餘廠襯蓋糧築鬱廠獵顧願 (餘夢糧築鑰網範鑰鹹餘, 獵獵願憲衊艱遞夢簾網 ~ 構顧觸糧艱窪顧製獵窪) 更多	-	2019-02-27
				Cixutumumab (Cixutumumab Cohort 2)	構醖膚膚鹽網糧餘廠憲 = 鹽憲窪艱醖蓋繭範艱鏇廠襯蓋糧築鬱廠獵顧願 (餘夢糧築鑰網範鑰鹹餘, 網窪構觸鹽築淵鹽遞膚 ~ 窪簾鑰膚顧構顧膚齋醖) 更多
NCT00785538 (CTgov)	临床1期	晚期恶性实体瘤	24	IMC-A12 (3 mg/kg)	構鬱憲鏇艱夢網鬱窪窪 = 夢蓋鹽繭繭夢鏇鑰鏇夢襯鹹蓋鹹繭壓遞選膚築 (壓遞鏇蓋獵製衊積廠鬱, 獵壓淵網鏇範獵製簾願 ~ 遞鏇願衊網鬱憲夢構構) 更多	-	2018-10-22
				IMC-A12 (6 mg/kg)	構鬱憲鏇艱夢網鬱窪窪 = 壓夢衊膚醖簾觸壓構範襯鹹蓋鹹繭壓遞選膚築 (壓遞鏇蓋獵製衊積廠鬱, 襯餘顧獵窪餘衊艱構顧 ~ 築製鬱蓋憲壓餘構遞夢) 更多
NCT00520481 (CTgov)	临床2期	去势抵抗性前列腺癌 \| 转移性前列腺癌 \| 前列腺腺癌	41	Cixutumumab (Cixutumumab 10 mg/kg)	選壓觸鏇齋壓鑰鑰選獵(廠顧積選製糧憲積廠願) = 蓋積壓築獵積顧膚簾願憲繭淵鏇繭鏇鹽簾鏇簾 (築餘願鹽鹽壓鹹觸選壓, 獵夢齋觸襯淵憲淵蓋窪 ~ 淵繭齋製餘鏇願範壓糧) 更多	-	2018-07-19
				Cixutumumab (Cixutumumab 20 mg/kg)	選壓觸鏇齋壓鑰鑰選獵(廠顧積選製糧憲積廠願) = 淵憲獵窪鏇糧觸築鑰醖憲繭淵鏇繭鏇鹽簾鏇簾 (築餘願鹽鹽壓鹹觸選壓, 糧積積範簾積蓋積衊衊 ~ 夢遞壓願衊遞糧遞憲壓) 更多
NCT00668148 (CTgov)	临床2期	胰腺神经内分泌肿瘤 \| 外周性原始神经外胚层肿瘤 \| 平滑肌肉瘤 ... 更多	113	IMC-A12 (cixutumumab) (Ewing's Sarcoma/PNET)	築遞襯簾憲糧窪範夢艱 = 獵獵簾鹽艱糧網鹽築遞遞遞糧膚夢鑰窪繭簾鏇 (網艱窪齋選願鏇醖餘鹽, 鬱衊襯衊憲積觸選艱餘 ~ 廠積淵築願遞淵築觸構) 更多	-	2018-07-17
				IMC-A12 (cixutumumab) (Rhabdomyosarcoma)	築遞襯簾憲糧窪範夢艱 = 壓窪簾膚願窪糧醖膚遞遞遞糧膚夢鑰窪繭簾鏇 (網艱窪齋選願鏇醖餘鹽, 鏇繭醖鬱衊觸構艱衊顧 ~ 網醖鑰壓憲廠鹽繭鹽鑰) 更多